Abstract
Emerging Infections Vaccines against Ebola virus (EBOV) are difficult to test in humans because of the sporadic nature of EBOV outbreaks. Therefore, understanding correlates of protection in preclinical models is necessary. Meyer et al. tested five candidate mucosal EBOV vaccines in cynomolgus macaques and showed that, despite sharing the same EBOV glycoprotein as an antigen, they varied in their ability to protect animals from EBOV challenge. The authors interrogated correlates of protection and found that functional qualities of the antibody response were associated with protection. By contrast, neutralizing antibody titers did not correlate with survival. Thus, looking beyond the presence of neutralizing antibodies may be necessary to understand the protective effect of EBOV vaccines. Sci. Transl. Med. 13 , eabg6128 (2021).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
